Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
June 25, 2024 07:00 ET
|
Fractyl Health, Inc.
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
Cardiometabolic Health Congress (CMHC) will present the results of a webcast series designed to help practitioners improve patient care
June 24, 2024 10:48 ET
|
Cardiometabolic Health Congress
Boca Raton, FL, June 24, 2024 (GLOBE NEWSWIRE) -- The ADA 2024 Scientific Sessions center on the latest cutting-edge advances in diabetes research, prevention, and care. The event will be held June...
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
June 24, 2024 07:00 ET
|
Rani Therapeutics, LLC
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism...
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
June 24, 2024 06:00 ET
|
Fractyl Health, Inc.
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
June 23, 2024 13:30 ET
|
Fractyl Health, Inc.
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Platform at ADA 2024.
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
June 20, 2024 11:37 ET
|
Zealand Pharma
Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide ...
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
June 14, 2024 09:00 ET
|
Elevai Labs Inc.
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
June 12, 2024 08:30 ET
|
Wave Life Sciences USA, Inc.
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for...
NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk
June 12, 2024 07:00 ET
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk ...
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
June 07, 2024 04:30 ET
|
Boehringer Ingelheim
News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH)...